NextPoint is a company focused on precision immuno-oncology and tumor-targeting therapeutics. They work on the B7-H7/HHLA2 axis, integrating foundational science with a defined clinical biomarker to identify patient populations for B7-H7-directed therapy.

NextPoint

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 checkpoint axis. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. NextPoint is simultaneously advancing therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology and beyond.

Sixty Degree Capital

Sanofi Ventures

PagodaTree Partners

Leaps by Bayer

MPM Capital

Invus

Binney Street Capital

Catalio Capital Management

Gordon Freeman

NextPoint Therapeutics, Inc.

#ICYMI, be sure to check out the poster @NextPoint presented at CIMT in May: “Targeting B7-H7-mediated immunosuppression with NPX267 and NPX887, two fully humanized monoclonal antibodies that target KIR3DL3 and B7-H7, respectively”

For more information on how NextPoint’s new class of therapeutics may improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.

We are thrilled to announce that our CEO, Ivan Cheung, will be speaking at the Longwood Healthcare Leaders Spring MIT event! Join us for two days of discussion and networking with biopharmaceutical leaders. Co-hosted by Koch Institute Professors Phil Sharp and Bob Langer and held at MIT’s Koch Institute, June 17-18, 2024. 

https://lnkd.in/exxKDits

Longwood Healthcare Leaders Longwood Fund #longwoodhealthcareleaders

Chief Medical Officer Leena Gandhi spoke last week at the Next-Gen Immuno-Oncology Conference in Boston about NextPoint Therapeutics, Inc.'s novel class of therapeutics targeting the B7-H7 pathway to improve treatment options for cancer therapy.

For more information on NextPoint’s new class of therapeutics to improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com.

Congratulations to NextPoint co-founder Dr. Gordon Freeman!

A nice behind the scenes look at how NextPoint scientific co-founder XingXing Zang's research translated to NPX267, our first clinical immuno-oncology program, currently in Phase 1a/1b clinical trials.

As we continue to push the boundaries of possibility, we are immensely grateful to be part of the LabCentral community.  LabCentral is the heart of our innovation and we're excited to share the impressive success of LabCentral and their 2023 Impact Report.

https://lnkd.in/eAxUk4T3

LabCentral has state-of-the-art facilities with access to top-tier resources where brilliant minds come together and make magic every day.  #Innovation #Collaboration #LabCentral #Science #Technology #Research

Qaraj

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

HSTS

Amazon

Chief Executive Officer

Rakesh Madhava

Vice President, Client Success

Tricia Boguslawski

Vice President / Brand + Creative

Michael Beumer

Project Director

Alexandria Spear

Client Success Director

Ben Thomas

Director of Engineering

Bryan Kerrigan

Marketing Director

Connor Jenkins

Head of Product

Daniel D'Angelo

Head of Client Success

Karen Mann-Anand

Director of People Operations

Kathryn Herforth

Founder & CEO

Elyse Ellman

Account Director

Brett Burney

eLaw Evangelist

Daniel D Angelo

VP, Client Success

Senior Account Executive

Director - Finance & Operations

Information Technology Companies with Private Equity Funding

Legal Companies With More Than 10 Employees (Top 10K)

Great Lakes Private Equity Stage Companies With Less Than $1B in Revenue

Chicago Companies With Fewer Than 1000 Employees (Top 10K)

Nextpoint develops regulatory, compliance, and litigation software applications.

Its products include Cloud Preservation, a tool for social media and website archiving; Discovery Cloud, an application to process, review, and produce digital evidence; and Trial Cloud, an application to manage evidence for litigation.

Nextpoint was founded in 2005 and is based in Chicago, Illinois.

RF Investment Partners

Private Equity Round - Nextpoint

Debt Financing - Nextpoint

Computer and Software Services and Scientific Services

Chicago

Illinois

United States

North America

Nextpoint

NXTPoint Logistics Welcomes Lee Kirk as New Chief Operating Officer

Nextpoint unveils T-cell engager for B7-H7-positive solid tumors

Nextpoint Announces Partnerships with Illinois, Wisconsin Bar Associations

Chutes & Ladders—Ex-Eisai leader Ivan Cheung tapped to be new CEO of NextPoint

Nextpoint obtains IND approval for NPX-887 for HHLA2-expressing solid tumors

RF aims to help law firms modernize with Nextpoint’s eDiscovery offerings

NextPoint strikes restructuring deal to sell assets

RF Investment Partners Adds to its Expanding Software Portfolio with Investment in Legal Tech Company Nextpoint

NextPoint Financial Inc. Announces Results of its Annual General Meeting

India

Asia

Israel

HTML5

Google Drive

Google Doubleclick

HubSpot Marketing Hub

Wistia

Lead Flows

Bootstrap

Adobe Flash

Cloudflare CDN

Wordpress

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 5, 2024 2:47 PM	4d308d38
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 30, 2024 12:11 AM	d0a3e6d4
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	441df60e
crunchbase profile	general	Oct 30, 2024 8:06 AM	b1675837
li profile	general	Aug 5, 2024 2:47 PM	20c11eb1
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	c4090f52
peers	general	Aug 5, 2024 2:47 PM	4ce287f0
news basic	general	Aug 5, 2024 2:47 PM	4c4b378b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NEXTPOINTTX

NextPoint